DrugDev Founder Melissa Easy is the 2015 Partnerships in Clinical Trials Woman of the Year

Share Article

Recognized for creating new technology-driven strategy that enables 9 of top 10 pharmaceutical sponsors and 4 of the 5 top CROs to conduct more clinical trials

Melissa Easy, President, DrugDev SiteStart

Liss's commitment makes it possible for pharma to test more promising new drugs.

DrugDev announced company founder and current President of DrugDev SiteStart Melissa (Liss) Easy is the 2015 Partnerships in Clinical Trials Woman of the Year.

The Woman of the Year award honors a leader in the clinical trials industry, a mentor and an advocate for other women in the organization. Organizers announced Liss’s selection at the Women’s Clinical Leadership Forum & Dinner during the conference. Liss was a finalist for the award in 2014.

Debra Chipman, CEO of IIR USA, which produces the Partnerships in Clinical Trials conference, said, “We congratulate Liss on this well-deserved honor. Throughout her career Liss has shown tremendous leadership in working to improve the way the pharmaceutical industry conducts clinical trials.”

Liss founded DrugDev to correct the inefficiencies in the process of matching clinical trial investigators to pharma protocols. Her mission is to bring sponsors and investigators closer together by focusing on the needs of the doctors and providing them with better technology-driven solutions, service, and more open communication.

DrugDev started with a network of cardiologists, and has since grown through referral and invitation into the world’s largest opted-in investigator network and data sharing platform, today reaching more than 80,000 active investigators in 115 countries who are actively seeking new clinical trial opportunities. DrugDev has expanded its suite of technology solutions to include contracting and regulatory document management known as SiteStart, Investigator payment services, a site optimization platform TrialNetworks, and a data solutions platform known as SiteCloud.

Ibraheem Mahmood, DrugDev President and CEO, said, “We’re delighted and not the least surprised Liss has achieved this wonderful recognition. She’s always believed technology and open communication can strengthen relationships between sponsors and investigators, and her commitment makes it possible for pharma to test more promising new drugs that otherwise might not see the light of day.”

Liss Easy said, “It’s a tremendous honor to be recognized for your passion, and I’m very grateful to IIR USA and the judges. I share this award with everyone at DrugDev who believes as I do that we can vastly improve patient quality of life if we improve the way we run clinical trials.”

Last month Liss was named to the Philadelphia Business Journal “40 Under 40” list which spotlights 40 dynamic, up-and-coming leaders less than 40 years of age for their professional accomplishments and community involvement.

About DrugDev

DrugDev is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs rely on DrugDev technology to do more trials at drugdev.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty
+1 617-688-3253
Email >

Kristopher Sarajian
617-952-4071 132
Email >
Follow >
Visit website